MIAMI, FLORIDA (Nov. 12, 2026) -- Researchers from Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine contributed to 91 poster presentations to be unveiled at ASH 2026 , the 68th-annual meeting and exposition of the American Society of Hematology in New Orleans, Dec. 12-15.
Below are the poster presentations with abstract links grouped into one of five categories: Myeloma, Leukemia, Lymphoma, Transplant / Cellular Therapy and Miscellaneous.
MYELOMA
Biochemical progression in treated high-risk smoldering myeloma predicts progression to active multiple myeloma: A pooled analysis of 9 prospective clinical trials
Body mass index, body composition, insulin resistance and metabolomics are associated with clinical outcomes during induction therapy in patients with newly diagnosed myeloma
Time-of-day administration of bispecific T-cell engagers in multiple myeloma: A retrospective, multi-institutional analysis
Dr. Abhishek Pandey is the presenting author.
Phase 2 randomized clinical trial of subcutaneous daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma (the ADVANCE trial): Updated progression-free survival analysis
Dr. Michael Durante is the presenting author.
Elranatamab (ELRA) plus iberdomide (IBER) in patients with relapsed or refractory multiple myeloma (RRMM): Dose-escalation results from the MagnetisMM-30 trial
A phase 3, multicenter, randomized, open-label study to evaluate the efficacy and safety of etentamig in combination with pomalidomide versus standard available therapies in patients with relapsed or refractory multiple myeloma
Large-scale genome-wide association meta-analyses double the number of multiple myeloma susceptibility loci
Ultra-sensitive detection of systemic minimal residual disease in multiple myeloma with paired-plus-minus sequencing of cell-free DNA
Chrissy Baker, M.Sc is the presenting author.
Targeting the SPT-ADA-GCN5 acetyltransferase chromatin-modifying complex and the transcriptional co-activator P300 as therapeutic vulnerabilities in multiple myeloma
Nelia Luviano Aparicio, Ph.D., is the presenting author.
Recurrent non-coding regulatory mutations Target TXNDC5 in multiple myeloma
Sreejeta Mondal, M.Sc, is the presenting author.
NFkB and RAS pathway activity are important predictors of high risk myeloma in computational modelling of presentation mutational profiles
Dommino-2: A Phase III, multicenter, open-label, randomized study to evaluate inobrodib in combination with pomalidomide and dexamethasone versus standard available therapy in patients with relapsed or refractory multiple myeloma
Longitudinal single-cell profiling reveals impaired monocyte activation and disrupted monocyte-T-cell cross-talk in bispecific antibody resistance in multiple myeloma
Palak Bajaj, M.S., is the presenting author.
A multicenter, phase 1b, open-label study of etentamig administered subcutaneously in patients with relapsed or refractory multiple myeloma
EPOCH as a debulking regimen in relapsed or refractory multiple myeloma: An emerging alternative to DCEP
Andrew Kowalski, Pharm.D., is the presenting author.
Matching-adjusted indirect comparisons (MAICs) of iberdomide + daratumumab + dexamethasone (IberDd) versus daratumumab + carfilzomib + dexamethasone (DKd) and isatuximab + carfilzomib + dexamethasone (IsaKd) in relapsed/refractory multiple myeloma (RRMM)
Dr. Ola Landgren is the presenting author.
Fixed duration iberdomide-based quadruplet therapy with de-escalation to monotherapy in early relapsed multiple myeloma: Primary endpoint and genomic analyses for the phase 2 rekindle study
Dr. Ola Landgren is the presenting author.
Frontline bispecific antibody-based therapy for quadruplet-eligible and quadruplet-ineligible patients with newly diagnosed multiple myeloma: The ADVANCE 2.0 study
Dr. Ola Landgren is the presenting author.
Single-cell multiomic analysis identifies a convergent, clinically high-risk myeloma cell state characterized by MYC, RB/E2F, and MTORC activation
Single-step marker-directed isolation and barcoding for single-cell RNA sequencing of multiple myeloma plasma cells from limited bone marrow input
LEUKEMIA
Myeloid neoplasia in telomere biology disorders: A CCCTAA multicenter study
Tuscany study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
Iadademstat combination with gilteritinib is a safe and effective treatment in FLT3-mutated relapsed/refractory acute myeloid leukemia: Topline results of the FRIDA trial.
Dr. Sangeetha Venugopal is the presenting author.
Mipletamig in combination with azacitidine and venetoclax in newly diagnosed CD123+ AML: Clinical update from the phase 1b rainier dose-optimization trial (APVO436-5201, NCT05303076)
Dr. Justin M Watts is the presenting author.
Trials in progress: A multicenter phase 1b study of the bispecific T-cell engager cln-049 in combination with venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia (AML)
Dr. Namrata S. Chandhok is the presenting author.
A prospective multicenter phase II study of venetoclax in combination with cladribine and low-dose cytarabine alternating with azacitidine plus venetoclax in monocytic and RAS/RTK pathway-mutated AML
Imetelstat plus ruxolitinib in patients with intermediate-1/2 or high-risk myelofibrosis: Updated results from the IMproveMF trial
Selective benefit in higher-risk MDS vs. broad efficacy in AML: Defining HMA+venetoclax clinical benefit using the PRISM score in 5,751 patients- an analysis from the validate database of the International Consortium for MDS (icMDS)
EpCAM identifies CD25-complementary leukemia stem cells and an AML fitness dependency
Updated anti-leukemia activity from a Phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T cell engager, in relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
A phase 1 study of PRT12396, a JAK2 V617F mutant-selective inhibitor, in patients with polycythemia vera or myelofibrosis
A multicenter, Phase Ib/II combination study of luspatercept and lenalidomide (L2) in lower-risk, non-del(5q) MDS patients: Final results
Dr. Mikkael A. Sekeres is the presenting author.
New and updated efficacy and safety data on bexobrutideg (NX-5948), a novel BTK degrader, in patients with relapsed/refractory CLL/SLL and prior cBTKi exposure from an ongoing phase 1a/b trial
Real-world practice patterns of FLT3 molecular testing and targeted therapy delivery in newly diagnosed acute myeloid leukemia
Dr. Meenakkshy Manoharan is the presenting author.
Enzomenib dose optimization and determination of the recommended Phase 2 dose in patients (pts) with relapsed or refractory NPM1m acute leukemia
Ruxolitinib plus duvelisib demonstrates encouraging efficacy in T-prolymphocytic leukemia
Trial in progress: EXCALIBUR-ET2, an international, randomized phase 3 trial of the mutant calreticulin-directed monoclonal antibody INCA033989 vs best available therapy in patients with high-risk essential thrombocythemia after inadequate response to cytoreductive therapy
Mutant CALR-specific monoclonal antibody INCA033989 improved disease burden, including splenomegaly, symptoms, and anemia, as monotherapy or in combination with ruxolitinib in patients with myelofibrosis and relapsed, refractory, or suboptimal response to prior therapy in a Phase 1 study
Pirtobrutinib (Pirto) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): A multicenter real-world evidence (RWE) study.
The marine compound elatol engages a novel mitochondrial bioenergetic checkpoint to selectively kill oxphos-reliant leukemias
Paola Manara, PhD, is the presenting author.
Genomic proximity mapping identifies clinically relevant cryptic structural variants and improves ELN risk stratification in acute myeloid leukemia
Revising response criteria for myelodysplastic/myeloproliferative neoplasm overlap syndromes: Methodology, consensus, and key controversies from the international working group
Identification of splenic B-cell lymphoma with prominent nucleoli in the hairy cell leukemia patient data registry
Phase 2 trial of venetoclax in patients with classic and variant hairy cell leukemia.
Clinical characteristics and outcomes of untreated patients with hairy cell leukemia. a retrospective cohort from the hclf patient data registry
JAK1/2 inhibition with ruxolitinib in relapsed/refractory bone marrow failure: Final report of a phase I/II clinical trial
A phase 1/2 study to evaluate the safety and efficacy of dibotatug (DR-01), a non-fucosylated anti-CD94 antibody, in adults with bone marrow failure syndromes
Agent orange exposure and the risk of developing myeloproliferative neoplasms among Vietnam veterans from the Million Veteran Program
LYMPHOMA
Cooperative loss of TET2 and DNMT3A drives TFH lymphomagenesis with therapeutic vulnerability to JAK-STAT and PI3K inhibition
BTKi-based chemotherapy-free frontline treatment of mantle cell lymphoma (MCL): A multicenter retrospective study
Long-term overall and lymphoma free survival of mantle cell lymphoma (MCL) in patients treated with R-MACLO-IVAM followed by maintenance -- analysis of two prospective trials and real-world experience.
Dr. Georgios N. Pongas is the presenting author.
Development and external validation of a time-based endpoint (ATL4) for early treatment failure in aggressive adult T-cell leukemia/lymphoma subtypes
Dr. Ana S. Salazar is the presenting author.
A pooled analysis of ctDNA MRD dynamics and clinical outcomes across the LOTIS clinical program
Dr. Juan Pablo Alderuccio is the presenting author.
Real-world treatment patterns, clinical, and economic outcomes following covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy in patients with mantle cell lymphoma (MCL) in the United States
Dr. Alvaro Alencar is the presenting author.
Baseline PET SUVmax identifies differential risk of histologic transformation according to frontline therapy in follicular lymphoma
Survival outcomes of transformed marginal zone lymphoma (MZL) to diffuse large B-cell lymphoma (DLBCL): Distinct effects of treatment modalities by timing of transformation
Dr. Georgios N. Pongas is the presenting author.
Survival and cause of death in patients with newly diagnosed advanced-stage marginal zone lymphoma - prospective real-world multi-institutional study
Dr. Juan Pablo Alderuccio is the presenting author.
Silencing of Tet1 enhances plasma cell differentiation and drives autoimmune-like polyclonal gammopathy
Tom Haim Podolsky, M.Sc, is the presenting author.
Using event-free survival at 24 months and baseline FLIPI24 to identify cure in follicular lymphoma
Age-related differences in cumulative toxicity among children, adolescents, and young adults treated for high-risk Hodgkin lymphoma on the Children's oncology group AHOD1331 study
Interim analysis of dose escalation and dose optimization in the phase 1 PRIMAVERA study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma
The impact of socioeconomic factors in treatment delays in patients with DLBCL treated at a community hospital
Dr. Toral Manesh Shastri is the presenting author.
Cooperative loss of TET2 and TSC2 drives metabolic and transcriptional reprogramming in human CD4? T cells relevant to TFH lymphomagenesis
HTLV-1 integration site sequencing as a powerful tool for characterizing deep molecular responses in ATLL patients undergoing therapy
Role of a unique subset of cytolytic T cells in clinical response in the belinostat trial with zidovudine plus interferon for adult T-cell leukemia/lymphoma
A multi-center real-world experience of lenalidomide and rituximab for patients with relapsed or refractory follicular lymphoma
A phase 2 trial of abbreviated BrECADD (Brentuximab Vedotin, Etoposide, Cyclophosphamide, Adriamycin, Dacarbazine, and Dexamethasone) therapy in stage IIb-IV Hodgkin lymphoma
Dr. Michele D. Stanchina is the presenting author.
The combination of nivolumab and duvelisib leads to repeated immune-mediated toxicities in cutaneous T-cell lymphoma: Clinical results of an experimental therapeutics clinical trials network (ETCTN) study 10347
A longitudinal analysis of patient reported outcomes in patients with cutaneous T-cell lymphoma in the lymphoma epidemiology of outcomes (LEO) study
Improvement in outcomes in peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH): An analysis of survival outcomes in nodal PTCL in the LEO prospective cohort
Diagnostic and staging practices in mycosis fungoides and Sézary syndrome: A multicenter analysis from the LEO-MER cohort.
Real world outcomes of glofitamab +/- polatuzumab vedotin in refractory/relapsed Burkitt lymphoma
Patient-reported cognitive impairment 3-5 years after lymphoma diagnosis: Risk factors from the prospective LEO cohort
TRANSPLANT & CELLULAR THERAPY
Frailty status is more strongly associated with survival compared to age or comorbidity in older adults prior to allogeneic hematopoietic stem cell transplantation
Dr. Noa G. Holtzman is the presenting author.
Patterns of progression by day 30 radiographic disease burden and hematologic response after ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Clinical overview of acute GVHD events with Orca-T compared to conventional allograft with tac/MTX in phase 3 precision-T trial
Standard of care chimeric antigen receptor (CAR-T) as second-line therapy in relapsed-refractory large B-cell lymphoma (LBCL)
Real-time single-cell interrogation during CAR-T treatment reveals a critical role for tumor MHC-I in infiltration and activation of the lymphoma microenvironment
Venu Venkatarame Gowda Saralamma, Ph.D., is the presenting author.
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after reduced-intensity mismatched unrelated donor peripheral blood stem cell transplantation: 2-year outcomes from the ACCESS trial
Development and validation of the SCOPE-MCL score: A pre-apheresis risk model predicting survival in patients with relapsed/refractory mantle cell lymphoma receiving CAR-T therapy
Two-year follow-up of Orca-T compared to conventional allogeneic hematopoietic stem cell transplant demonstrates durable survival outcomes: Updated results from the precision-T phase 3 trial
Pretransplant disease status predicts relapse while non-relapse mortality accumulates late after allogeneic HCT for mature T- and NK-cell lymphomas: A three-center U.S. cohort
Protocol of a multi-site randomized controlled trial of a multidisciplinary intervention for adults with chronic graft versus host disease (HORIZONS)
Joely Centracchio, M.S., is the presenting author.
MISCELLANEOUS
Apollo: Baseline characteristics of a phase 3, randomized, double-blind, placebo-controlled confirmatory study of bitopertin in adults and adolescents with erythropoietic protoporphyria or x-linked protoporphyria
Toward a single-assay solution for comprehensive genomic profiling in hematologic malignancies: Development and validation of a deep whole-genome sequencing assay
Advancing perioperative anticoagulation care through MDCALC: Implementation insights
A real-world analysis of pediatric attp in the age of caplacizumab
Comparative real-world safety of Bruton tyrosine kinase inhibitors: A pharmacovigilance analysis of ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib
Novel method of screening for multiethnic women at high risk of fetal-neonatal alloimmune thrombocytopenia: Identification of high risk and already-sensitized women
Individualized phenotype-directed prophylaxis in children and adolescents with von Willebrand disease: A real-world experience from a single pediatric center
Baseline clinical characteristics of females with hemophilia: Findings from ATHN Transcends
Dr. Fernando Corrales-Medina is the presenting author.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full
here.
